Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | PIM1 | P11309 | 3/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | LATS1 | O95835 | 2/20 | 0.30 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259154 | 0.90 | PIM1 (0.33) | PIM1PIM2P2RX3P2RX2LATS1 | |
| SCHEMBL3282577 | 0.79 | MAPK1 (0.37) | P2RX3P2RX2MAPK1SYK | |
| SCHEMBL3278084 | 0.74 | MB (0.41) | NPSR1MEN1KMT2AMAPK14HSD11B1 | |
| SCHEMBL21681868 | 0.65 | NPSR1 (0.45) | NPSR1MEN1KMT2AMAPK14HSD11B1 | |
| SCHEMBL24345747 | 0.64 | NPSR1 (0.41) | NPSR1MEN1KMT2AMAPK14HSD11B1 | |
| SCHEMBL3277903 | 0.64 | MB (0.41) | P2RX3P2RX2 | |
| SCHEMBL21047131 | 0.64 | NPSR1 (0.44) | NPSR1MEN1KMT2AMAPK14HSD11B1 | |
| SCHEMBL3278249 | 0.63 | MB (0.43) | — | |
| SCHEMBL3278309 | 0.62 | MKNK1 (0.49) | MEN1KMT2A | |
| SCHEMBL29045311 | 0.62 | NPSR1 (0.40) | NPSR1MEN1KMT2AMAPK14HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700768-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7629462-B2 | Tetrasubstituted pyrimidine compounds as chemical intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090048442-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| US-20070167467-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167467-A1 | 1,5-DISUBSTITUTED-3,4-DIHYDRO-1H-PYRIMIDO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CSBP/P38 KINASE MEDIATED DISEASES | MAPKAPK2, CREBBP, CNBP | NPSR1 3100/4885MEN1 4717/4885KMT2A 3558/4885 |
| US-20090048442-A1 | Novel compounds | CREBBP, MAPKAPK2, CNBP | NPSR1 3849/4885MEN1 4834/4885KMT2A 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.